Comparable stake leader
ACORN BIOVENTURES, L.P.
SEC ownership of Mural Oncology plc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001971543.
Disclosed value leader
ACORN BIOVENTURES, L.P.
Comparable rows
2/14
Latest evidence
05 Dec 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ACORN BIOVENTURES, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 14
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ACORN BIOVENTURES, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
05 Dec 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001971543
- Issuer location
- Dublin 2, Ireland
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Mural Oncology plc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ACORN BIOVENTURES, L.P.
Disclosed value leader
ACORN BIOVENTURES, L.P.
Comparable rows
2/14
Latest evidence
05 Dec 2025
13D/G
3/4/5
Lead comparable stake: 7.6%
12 rows are not safely comparable across share classes.
13D/G row: ACORN BIOVENTURES, L.P.
Showing 1-8 of 14 holder rows.
Quick read
ACORN BIOVENTURES, L.P. leads the comparable SEC ownership view at 7.6%.
2 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ACORN BIOVENTURES, L.P.'s linked filing trail.
Comparable ownership
Top 2
ACORN BIOVENTURES, L.P.
7.6%
Stuart Feldman
4.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
7.6%
|
$3,369,527
1,286,079 shares
|
+$547,205 | 31 Dec 2024 |
| Stuart Feldman |
13D/G
|
4.4%
|
$2,005,872
765,600 shares
|
$0 | 16 Apr 2025 |
| Trium Capital LLP |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
1,760,097 shares
|
— | 22 Aug 2025 |
| Cafico Trust Co Ltd |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
—
25,003 shares
mixed-class rows
|
— | 31 Oct 2023 |
| Caroline Loew |
3/4/5
Chief Executive Officer, Director
|
— |
$449,654
|
— | 05 Dec 2025 |
| Adam D. Cutler |
3/4/5
Chief Financial Officer
|
— |
$217,750
|
-$14,939 | 05 Dec 2025 |
| Maiken Keson-Brookes |
3/4/5
Chief Legal Officer
|
— |
$217,750
|
— | 05 Dec 2025 |
| Vicki L. Goodman |
3/4/5
Chief Medical Officer
|
— |
$217,750
|
-$10,475 | 05 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$25,414.
Buys
$0
Insiders: 0
Sells
$25,414
Insiders: 2
Net
-$25,414
Shares: -12,184
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 12,184
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 12,184 | $0 | $25,414 | -$25,414 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Mural Oncology plc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Caroline Loew
Net 12M change
-$25,414
Latest report
05 Dec 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Caroline Loew | Chief Executive Officer, Director | $449,654 | Mixed | 05 Dec 2025 | ||
| Vicki L. Goodman | Chief Medical Officer | $217,750 | -$10,475 | -4.6% | Mixed | 05 Dec 2025 |
| Maiken Keson-Brookes | Chief Legal Officer | $217,750 | Mixed | 05 Dec 2025 | ||
| Adam D. Cutler | Chief Financial Officer | $217,750 | -$14,939 | -6.4% | Mixed | 05 Dec 2025 |
| Susan Altschuller | Director | $60,419 | Mixed | 14 Aug 2024 | ||
| Sachiyo Minegishi | Director | $51,372 | Mixed | 05 Dec 2025 | ||
| George Golumbeski | Director | $51,369 | Mixed | 05 Dec 2025 | ||
| Francis M. Cuss | Director | $28,348 | Mixed | 05 Dec 2025 | ||
| Benjamin Hickey | Director | $28,348 | Mixed | 05 Dec 2025 | ||
| Scott Thomas Jackson | Director | $28,348 | Mixed | 05 Dec 2025 | ||
| Cafico Trust Co Ltd | 10%+ Owner | Mixed | 31 Oct 2023 | |||
| Trium Capital LLP | 10%+ Owner | Mixed | 22 Aug 2025 |
Recent insider transactions for Mural Oncology plc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Benjamin Hickey | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -32,120 | 0 | 05 Dec 2025 | Direct | ||
| Caroline Loew | MURA | Ordinary Shares | Disposed to Issuer | -100% | -293,059 | 0 | 05 Dec 2025 | Direct | ||
| Caroline Loew | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -603,940 | 0 | 05 Dec 2025 | Direct | ||
| Francis M. Cuss | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -32,120 | 0 | 05 Dec 2025 | Direct | ||
| Scott Thomas Jackson | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -32,120 | 0 | 05 Dec 2025 | Direct | ||
| George Golumbeski | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -23,971 | 0 | 05 Dec 2025 | Direct | ||
| Sachiyo Minegishi | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -23,972 | 0 | 05 Dec 2025 | Direct | ||
| Maiken Keson-Brookes | MURA | Ordinary Shares | Disposed to Issuer | -100% | -68,834 | 0 | 05 Dec 2025 | Direct | ||
| Maiken Keson-Brookes | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -150,442 | 0 | 05 Dec 2025 | Direct | ||
| Vicki L. Goodman | MURA | Ordinary Shares | Disposed to Issuer | -100% | -84,727 | 0 | 05 Dec 2025 | Direct | ||
| Vicki L. Goodman | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -200,604 | 0 | 05 Dec 2025 | Direct | ||
| Adam D. Cutler | MURA | Ordinary Shares | Disposed to Issuer | -100% | -99,290 | 0 | 05 Dec 2025 | Direct | ||
| Adam D. Cutler | MURA | Stock Option (right to buy) | Disposed to Issuer | -100% | -211,452 | 0 | 05 Dec 2025 | Direct | ||
| Vicki L. Goodman | MURA | Ordinary Shares | Sale | -5.61% | $10,475 | $2.08 | -5,036 | 84,727 | 10 Nov 2025 | Direct |
| Adam D. Cutler | MURA | Ordinary Shares | Sale | -6.72% | $14,939 | $2.09 | -7,148 | 99,290 | 03 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.